Long-term outcome of resuming anticoagulation after anticoagulation-associated intracerebral hemorrhage

Alireza Sadighi; Lisa Wasko; Heather DiCristina; Thomas Wagner; Kathryn Wright; Kellie Capone; Maureen Monczewski; Margaret Kester; George Bourdages; Christoph Griessenauer; Ramin Zand

doi:10.1016/j.ensci.2020.100222

Long-term outcome of resuming anticoagulation after anticoagulation-associated intracerebral hemorrhage

eNeurologicalSci. 2020 Jan 17:18:100222. doi: 10.1016/j.ensci.2020.100222. eCollection 2020 Mar.

Affiliations

¹ Department of Neurology, Geisinger Medical Center, Danville, PA, USA.
² Department of Neurosurgery, Geisinger Medical Center, Danville, PA, USA.

Abstract

Introduction: The risk and benefit of restarting oral anticoagulation (OAC) therapy among patients with atrial fibrillation or flutter (AF) and an episode of anticoagulation-associated intracerebral hemorrhage (ICH) remain unclear. Whether or not to resume OAC after an OAC-associated ICH will remain an unanswered clinical question until we have sufficient data through randomized clinical trials. Here, we analyzed the long-term outcome of patients with AF who did or did not resume OAC after an OAC-associated ICH.

Patients and methods: We studied consecutive patients with AF who were discharged from our institution after an OAC-associated ICH event between 2010 and 2017. Baseline characteristics of patients, past medical history, and history or OAC use were recorded. Outcome measures in our study included recurrent ICH, ischemic stroke or systemic emboli, and death.

Results: Out of 115 patients with AF and OAC-associated ICH, 93 patients (mean age 76.2 ± 10.3 years [44-91 years old], 54.3% men) were included in this study. Thirty-eight (40.9%) patients resumed OAC after the episode of OAC-associated ICH. More than 70% of patients had resumed OAC within two months of ICH (mean delay 56.0 ± 52.5 days). There was no significant difference between the group who resumed OAC and the group who did not in terms of mean follow-up duration (1.9 vs. 2.4 years), the type of initial ICH, as well as history of hypertension, diabetes, previous ischemic stroke, congestive heart failure, coronary artery disease, and tobacco use. There was no significant difference between the two groups considering the incidence rate of recurrent ICH (relative risk 2.9; 95% CI, 0.3-30.8). There was also no significant difference between the two groups regarding the incidence rate of ischemic stroke or systemic emboli (relative risk 0.9; 95% CI, 0.3-2.7). There was no significate difference between patients who did and did not resume OAC was 96 and 121 per 1000 patient-years, respectively (relative risk 0.8; 95% CI, 0.3-1.9).

Conclusions: We did not observe any significant difference between the group of patients who resumed OAC and the patients who did not in terms of recurrent ICH, ischemic stroke or systemic emboli, and death. However, there was a tendency toward a higher long-term risk of recurrent ICH among patients who resumed OAC.

Keywords: Anticoagulation; Atrial fibrillation; Intracerebral hemorrhage.